VectorY raises €74.5 million to advance ALS therapy trial
Image: EU-Startups VectorY Therapeutics has raised €74.5 million ($83.5 million) to advance its experimental therapies for neurodegenerative diseases. New investors include Angelini Ventures, Invest-NL and the European Investment Bank, alongside returning backers.
The financing will mainly support VTx-002 in its ongoing PIONEER-ALS Phase 1/2 trial in adults with ALS across the US, Europe and the UK. VectorY combines therapeutic antibodies with one-time viral delivery directly to the central nervous system. The money will also support its Huntington's disease programme and other preclinical work; the ALS treatment remains investigational.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from EU-Startups and reviewed by the T&B editorial agent team.
Back to Newswire
